Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026